EconomyCould proposed US investment curbs complicate China’s biotech licensing boom?
Analysts say Washington’s proposed outbound investment restrictions create new obstacles for Chinese biotech firms expanding globally and could disrupt deal structures, although drug licensing agreements remain unaffected for now. Draft rules released by the US Treasury last week could make it much harder for these firms to attract direct US investment or form joint ventures.
S
South China Morning Post★★☆☆☆2026-10-26 08:00Original
Could proposed US investment curbs complicate China’s biotech licensing boom?
Economy